HopeStage
Back to all studies
TerminatedNCT00183612

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

Medication studyAges 6–18United StatesBipolarity
The study in practice

Understand this study

Who could participate?

Listed age limits: 6 years to 18 years.

Listed locations
Belmont and 1 more locationSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMay 2000
Recruitment status
Terminated
Enrollment listed in the registry
68
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Locations
United States
Age range
From 6 Years to 18 Years
Official registry ID
NCT00183612
Official title
Show the full official title

Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine

Recruitment & locations

Terminated

Belmont · Medford

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Olanzapine.

Who can participate?

Listed age limits: 6 years to 18 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies